Page last updated: 2024-10-18

dalteparin and Cardiomyopathies

dalteparin has been researched along with Cardiomyopathies in 2 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Park, JL1
Tanhehco, EJ1
Kilgore, KS1
Gralinski, MR1
Lucchesi, BR1
Strobel, J1
Schröder, S1

Other Studies

2 other studies available for dalteparin and Cardiomyopathies

ArticleYear
Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart.
    Journal of cardiovascular pharmacology, 1997, Volume: 30, Issue:5

    Topics: Animals; Anticoagulants; Cardiomyopathies; Complement Activation; Complement C3 Convertase, Alternat

1997
[Postpartum cardiomyopathy].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:22

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticoagula

2011